Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »
Feb 1, 2009 (Vol. 29, No. 3)

GEN’s Annual Wall Street Roundup

Experts Agree that Adaptability Is the Key to Long-Term Survival, Especially in Difficult Times

  • Survival of the fittest has governed life on Earth since the beginning of time, but it was first defined only 150 years ago by Charles Darwin. Today, it couldn’t be any more obviously at play, with economic turmoil necessitating a shakedown in the biotechnology sector.

    Biotech industry experts agree that financing will be tough in the short term. Smaller companies, in particular, will need to comb through their pipelines and rethink strategies. Additionally, political currents will buoy research and follow-on biologics, but could have an impact on big pharma and drug pricing. 

    GEN asked biotech analysts to predict what’s in store for the biotech industry in terms of the new political regime, as well as the current financial distress, and to provide some survival tips. Our respondents were Benjamin J. Conway, managing director with Johnston Blakely & Company, Nola E. Masterson, managing director of Science Futures, Viren Mehta, managing member of Mehta Partners, Jason Napodano, senior biotechnology analyst at Zacks Investment Research, Rod Raynovich, principal at Raygent Associates, and John L. Sullivan, director of research at Leerink Swann.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »